Trial reportBone marrow transplantation2015
Fecal calprotectin and α1-antitrypsin dynamics in gastrointestinal GvHD.
Trial report in Bone marrow transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Non-invasive diagnosis of acute intestinal graft-versus-host disease by a new scoring system using ultrasound morphology, compound elastography, and contrast-enhanced ultrasound.Bone marrow transplantation · 2019Trial
- Fecal calprotectin as a biomarker for the diagnosis of gastrointestinal graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.Bone marrow transplantation · 2026Observational
- Fecal Calprotectin as a biomarker for early diagnosis and prediction of steroid response in Acute Gastrointestinal Graft versus Host Disease.Blood cell therapy · 2026Article
- Unlocking protein-based biomarker potential for graft-versus-host disease following allogenic hematopoietic stem cell transplants.Frontiers in immunology · 2024Review
- Factors associated with anaemia among preschool- age children in underprivileged neighbourhoods in Antananarivo, Madagascar.BMC public health · 2022Article
- Immunopathology and biology-based treatment of steroid-refractory graft-versus-host disease.Blood · 2020Review
- Review
- Baseline calprotectin fails to predict incidence of acute gastrointestinal graft vs. host disease: a prospective study.Bone marrow transplantation · 2019Article
- Alpha-1 Antitrypsin Substitution for Extrapulmonary Conditions in Alpha-1 Antitrypsin Deficient Patients.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2018Article
- Faecal Calprotectin.The Clinical biochemist. Reviews · 2018Review
- The enteric virome in hematopoietic stem cell transplantation: ready for its close-up.Nature medicine · 2017Article
- The eukaryotic gut virome in hematopoietic stem cell transplantation: new clues in enteric graft-versus-host disease.Nature medicine · 2017Article
- Endoscopic and Histological Findings Are Predicted by Fecal Calprotectin in Acute Intestinal Graft-Versus-Host-Disease.Digestive diseases and sciences · 2016Article
- Danger Signals and Graft-versus-host Disease: Current Understanding and Future Perspectives.Frontiers in immunology · 2016Review
- Understanding Luminal Microorganisms and Their Potential Effectiveness in Treating Intestinal Inflammation.Inflammatory bowel diseases · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In a previous study, the fecal biomarkers calprotectin and α1-antitrypsin (α1-AT) at symptom onset were reported to be significantly associated with the response to steroids in gastrointestinal GvHD (GI-GvHD). The purpose of this trial was to evaluate the dynamics of the fecal biomarkers calprotectin and α1-AT throughout the course of GvHD. Patients who were refractory to steroids had initially higher biomarker levels and in the course of GvHD demonstrated a continuous increase in fecal biomarkers. In contrast, the dynamics of calprotectin and α1-AT demonstrated low and decreasing levels in cortico-sensitive GvHD. In steroid-refractory patients who received a second line of treatment, the biomarker levels at the beginning of second-line treatment did not predict the subsequent response. Nevertheless, calprotectin levels progressively decreased in subsequent responders, whereas non-responders demonstrated continuously high levels of calprotectin. α1-AT values correlated to a lesser extent with the response to second-line treatment and remained elevated in both non-responders and responders. In conclusion, calprotectin monitoring can be of use in the management of immunosuppressive treatment in GI-GvHD.
Indexed as
Identifiers
25961766What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.